Nichtrheumatisches Vorhofflimmern und antithrombotische Therapie

K. Huber; D. C. Gulba; F. W. A. Verheugt

doi:10.1055/s-0038-1660015

Hämostaseologie, Table of Contents

Hamostaseologie 1997; 17(01): 61-65
DOI: 10.1055/s-0038-1660015

Antithrombotische Strategien in der Kardiologie

Schattauer GmbH

Nichtrheumatisches Vorhofflimmern und antithrombotische Therapie

K. Huber

,

D. C. Gulba

,

F. W. A. Verheugt

Abstract

Full Text

References

LITERATUR
1 Aronow WS. Correlation of arrhythmias and conduction defects on the resting electrocardiogram with new cardiac events in 1153 elderly patients. Am J Noninvasive. Cardiol 1991; 5: 88-90.
2 Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am J Cardiol 1989; 63: 366-7.
3 Atrial Fibrillation Investigators.. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449-57.
4 BAATAF.. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke patients with nonrheumatic atrial fibrillation. New Engl J Med 1990; 323: 1505-11.
5 Cabin HS, Clubb S, Hall C. et al. Risk of systemic embolisation in atrial fibrillation without mitral stenosis. 1990; 65:1112-6.
6 Connolly SJ, Laupacis A, Gent M. et al. For the CAFA study coinvestigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-55.
7 Davenport RJ, Warlow CP. Warfarin or aspirin for non-rheumatic atrial fibrillation. Vessels 1996; 2: 11-20.
8 EAFT (European atrial fibrillation trial) study group.. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
9 Ezekowitz MD, Bridges SL, James KE. et al. For the Veteran Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation investigators. Warfarin in the prevention of stroke associated with nonrheumatic and atrial fibrillation. N Engl J Med 1992; 327: 1406-12.
10 Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; I: 526-9.
11 Gustafsson C, Blomback M, Britton M. et al. Coagulation factors and the increased risk of stroke in non-valvular atrial fibrillation. Stroke 1990; 21: 47-51.
12 Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med 1996; 540-6
13 Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiological features of chronic atrial fibrillation. N Engl J Med 1982; 306: 1018-22.
14 Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: The Framingham study. Am Heart J 1983; 106: 389-96.
15 Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest 1992; 426S-433S.
16 Mitusch R, Siemens HJ, Garbe M. et al. Detection of a hypercoagulable state in non-valvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost 1996; 75: 210-23.
17 Mounier-Vehier F, Leys D, Rondepierre P. et al. Silent infarcts in patients with ischemic stroke are related to age and size of the left atrium. Stroke 1993; 24: 1347-51.
18 Petersen P, Boysen G, Godtfredsen J. et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989; 1: 175-9.
19 Pumphrey CW, Fuster V, Cheseboro HJ. Systemic thromboembolism in valvular heart disease and prosthetic heart valves. Mod Concepts Cardiovasc Dis 1982; 51: 131-6.
20 Rose G, Baxter PJ, Reid DD, McCartney P. Prevalence and prognosis of electrocardiographic findings in middle-aged men. Br Heart J 1978; 40: 636-43.
21 SPAF-1.. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-39.
22 SPAF-2.. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91.
23 SPAF-3 Investigators.. Adjusted-dose warfarin versus low-intensity; fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.
24 The Stroke Pervention in Atrial Fibrillation Investigators.. Predictors of thromboembolism in atrial fibrillation: 1. Clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
25 The Stroke Prevention in Atrial Fibrillation Investigators.. Predictors of thromboembolism in atrial fibrillation: 2. Echocardiogra-phic features of patients at risk. Ann Intern Med 1992; 116: 6-12.
26 Weiner I, Hafner R, Nicolai M, Lyons H. Clinical and echocardiographic correlates of systemic embolisation in non-rheumatic atrial fibrillation. Am J Cardiol 1987; 59: 177-9.
27 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke. The Framingham study. Stroke 1991; 22: 983-8.
28 Wolf PA, Abbott RD, Kannell WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 1987; 147: 1561-4.
29 Wolf PA, Dawber TR, Thomas HEJ, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke; the Framingham study. Neurology 1978; 28: 973-7.